SOMERVILLE, Mass.– Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer to oversee all clinical matters.
“We’re delighted Alex is joining the Generate Biomedicines team as we move our lead programs through IND enabling studies and toward the clinic,” said Mike Nally, Generate’s Chief Executive Officer. “Her impressive clinical experience, patient focus, and demonstrated leadership track record are crucial additions to our team as we pioneer the field of generative biology and pursue a broad portfolio of medicines.”
Dr. Snyder remarked, “Generate is revolutionizing drug development through a powerful new approach to creating protein therapeutics. I am thrilled to be part of such a talented team that will dramatically improve our ability to solve complex biological challenges and help improve the lives of patients with a broad range of medical conditions.”
Most recently, Dr. Snyder was a principal at the private equity firm Two River where she was responsible for setting the translational and clinical strategy and execution for Two River’s portfolio of novel biotech companies. Previously she was the Head of Translational Oncology at Merck. In this role, Dr. Snyder was responsible for conducting Merck-sponsored clinical trials across pipeline combination therapies at worldwide sites and the companion diagnostic strategy, biomarker programs and quantitative pharmacology for oncology clinical trials. Prior to joining industry, she practiced oncology at Memorial Sloan Kettering Cancer Center; she is currently a voluntary faculty member at Bellevue Hospital and New York University.
Dr. Snyder graduated summa cum laude from Princeton University with a degree in history and a minor in music. She received her medical education at Mount Sinai Medical School, graduated with the highest overall standing, and was an internal medicine resident at Mount Sinai Hospital and a medical oncology fellow at Memorial Sloan Kettering Cancer Center.
